‘TREMENDOUS WIN:’ Tetra Therapeutics’ sale offers healthy returns for investors, validation for local ecosystem
This is an article about portfolio company, Tetra Therapeutics
GRAND RAPIDS — Tetra Therapeutics Inc.’s sale to a Japanese pharmaceutical company provides a final pathway toward bringing to market potential new drugs to treat Alzheimer’s disease and a form of autism, as well as generates a handsome return for financial backers.
Investors in a $7.2 million Series A capital round Tetra raised in 2016 got a return of five times their original investment, founder and CEO Mark Gurney said. Participants in an earlier July 2013 debt offering got an ROI that’s close to 13 times their investment, he said.